ID   PLD3_HUMAN              Reviewed;         490 AA.
AC   Q8IV08; Q92853; Q9BW87;
DT   20-MAR-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2003, sequence version 1.
DT   18-JUN-2025, entry version 175.
DE   RecName: Full=5'-3' exonuclease PLD3 {ECO:0000305};
DE            EC=3.1.16.1 {ECO:0000269|PubMed:30111894, ECO:0000269|PubMed:30312375};
DE   AltName: Full=(S,S)-bis(monoacylglycero)phosphate synthase PLD3 {ECO:0000305|PubMed:39423811};
DE            EC=3.1.4.- {ECO:0000269|PubMed:39423811};
DE   AltName: Full=HindIII K4L homolog;
DE   AltName: Full=Hu-K4 {ECO:0000303|PubMed:15794758};
DE   AltName: Full=Phospholipase D3;
GN   Name=PLD3 {ECO:0000303|PubMed:26411346, ECO:0000312|HGNC:HGNC:17158};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Mammary gland;
RX   PubMed=9140189; DOI=10.1016/s0168-1702(96)01422-0;
RA   Cao J.X., Koop B.F., Upton C.;
RT   "A human homolog of the vaccinia virus HindIII K4L gene is a member of the
RT   phospholipase D superfamily.";
RL   Virus Res. 48:11-18(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, Colon, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   SUBCELLULAR LOCATION, TOPOLOGY, TISSUE SPECIFICITY, AND GLYCOSYLATION.
RX   PubMed=15794758; DOI=10.1111/j.1742-4658.2005.04601.x;
RA   Munck A., Boehm C., Seibel N.M., Hashemol Hosseini Z., Hampe W.;
RT   "Hu-K4 is a ubiquitously expressed type 2 transmembrane protein associated
RT   with the endoplasmic reticulum.";
RL   FEBS J. 272:1718-1726(2005).
RN   [4]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-97 AND ASN-132.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [6]
RP   SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-418, AND FUNCTION.
RX   PubMed=22428023; DOI=10.1371/journal.pone.0033341;
RA   Osisami M., Ali W., Frohman M.A.;
RT   "A role for phospholipase D3 in myotube formation.";
RL   PLoS ONE 7:E33341-E33341(2012).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [8]
RP   FUNCTION, POSSIBLE INVOLVEMENT IN ALZHEIMER DISEASE, VARIANT MET-232,
RP   TISSUE SPECIFICITY, AND INTERACTION WITH APP.
RX   PubMed=24336208; DOI=10.1038/nature12825;
RG   UK Brain Expression Consortium;
RA   Cruchaga C., Karch C.M., Jin S.C., Benitez B.A., Cai Y., Guerreiro R.,
RA   Harari O., Norton J., Budde J., Bertelsen S., Jeng A.T., Cooper B.,
RA   Skorupa T., Carrell D., Levitch D., Hsu S., Choi J., Ryten M., Hardy J.,
RA   Ryten M., Trabzuni D., Weale M.E., Ramasamy A., Smith C., Sassi C.,
RA   Bras J., Gibbs J.R., Hernandez D.G., Lupton M.K., Powell J., Forabosco P.,
RA   Ridge P.G., Corcoran C.D., Tschanz J.T., Norton M.C., Munger R.G.,
RA   Schmutz C., Leary M., Demirci F.Y., Bamne M.N., Wang X., Lopez O.L.,
RA   Ganguli M., Medway C., Turton J., Lord J., Braae A., Barber I., Brown K.,
RA   Passmore P., Craig D., Johnston J., McGuinness B., Todd S., Heun R.,
RA   Kolsch H., Kehoe P.G., Hooper N.M., Vardy E.R., Mann D.M.,
RA   Pickering-Brown S., Brown K., Kalsheker N., Lowe J., Morgan K.,
RA   David Smith A., Wilcock G., Warden D., Holmes C., Pastor P.,
RA   Lorenzo-Betancor O., Brkanac Z., Scott E., Topol E., Morgan K., Rogaeva E.,
RA   Singleton A.B., Hardy J., Kamboh M.I., St George-Hyslop P., Cairns N.,
RA   Morris J.C., Kauwe J.S., Goate A.M.;
RT   "Rare coding variants in the phospholipase D3 gene confer risk for
RT   Alzheimer's disease.";
RL   Nature 505:550-554(2014).
RN   [9]
RP   LACK OF INVOLVEMENT IN ALZHEIMER DISEASE, AND VARIANTS SER-63; ALA-76;
RP   MET-159; CYS-162; SER-173; GLY-175; CYS-188; HIS-222; MET-232; GLN-242;
RP   GLY-249; CYS-272; SER-284; VAL-293; LEU-297; TYR-300; PRO-308; ILE-358;
RP   ALA-426 AND ARG-429.
RX   PubMed=26411346; DOI=10.1002/humu.22908;
RG   Belgium Neurology (BELNEU) Consortium and the European Early-Onset Dementia (EU EOD) Consortium;
RA   Cacace R., Van den Bossche T., Engelborghs S., Geerts N., Laureys A.,
RA   Dillen L., Graff C., Thonberg H., Chiang H.H., Pastor P., Ortega-Cubero S.,
RA   Pastor M.A., Diehl-Schmid J., Alexopoulos P., Benussi L., Ghidoni R.,
RA   Binetti G., Nacmias B., Sorbi S., Sanchez-Valle R., Llado A., Gelpi E.,
RA   Almeida M.R., Santana I., Tsolaki M., Koutroumani M., Clarimon J., Lleo A.,
RA   Fortea J., de Mendonca A., Martins M., Borroni B., Padovani A., Matej R.,
RA   Rohan Z., Vandenbulcke M., Vandenberghe R., De Deyn P.P., Cras P.,
RA   van der Zee J., Sleegers K., Van Broeckhoven C.;
RT   "Rare variants in PLD3 do not affect risk for early-onset Alzheimer disease
RT   in a European consortium cohort.";
RL   Hum. Mutat. 36:1226-1235(2015).
RN   [10]
RP   LACK OF INVOLVEMENT IN ALZHEIMER DISEASE, AND VARIANT MET-232.
RX   PubMed=25832408; DOI=10.1038/nature14036;
RA   Lambert J.C., Grenier-Boley B., Bellenguez C., Pasquier F., Campion D.,
RA   Dartigues J.F., Berr C., Tzourio C., Amouyel P.;
RT   "PLD3 and sporadic Alzheimer's disease risk.";
RL   Nature 520:E1-E1(2015).
RN   [11]
RP   LACK OF INVOLVEMENT IN ALZHEIMER DISEASE, AND VARIANT MET-232.
RX   PubMed=25832410; DOI=10.1038/nature14038;
RA   van der Lee S.J., Holstege H., Wong T.H., Jakobsdottir J., Bis J.C.,
RA   Chouraki V., van Rooij J.G., Grove M.L., Smith A.V., Amin N., Choi S.H.,
RA   Beiser A.S., Garcia M.E., van Ijcken W.F., Pijnenburg Y.A.,
RA   Louwersheimer E., Brouwer R.W., van den Hout M.C., Oole E.,
RA   Eirkisdottir G., Levy D., Rotter J.I., Emilsson V., O'Donnell C.J.,
RA   Aspelund T., Uitterlinden A.G., Launer L.J., Hofman A., Boerwinkle E.,
RA   Psaty B.M., DeStefano A.L., Scheltens P., Seshadri S., van Swieten J.C.,
RA   Gudnason V., van der Flier W.M., Ikram M.A., van Duijn C.M.;
RT   "PLD3 variants in population studies.";
RL   Nature 520:E2-E3(2015).
RN   [12]
RP   LACK OF INVOLVEMENT IN ALZHEIMER DISEASE, AND VARIANT MET-232.
RX   PubMed=25832411; DOI=10.1038/nature14039;
RA   Heilmann S., Drichel D., Clarimon J., Fernandez V., Lacour A., Wagner H.,
RA   Thelen M., Hernandez I., Fortea J., Alegret M., Blesa R., Mauleon A.,
RA   Roca M.R., Kornhuber J., Peters O., Heun R., Froelich L., Huell M.,
RA   Heneka M.T., Ruether E., Riedel-Heller S., Scherer M., Wiltfang J.,
RA   Jessen F., Becker T., Tarraga L., Boada M., Maier W., Lleo A., Ruiz A.,
RA   Noethen M.M., Ramirez A.;
RT   "PLD3 in non-familial Alzheimer's disease.";
RL   Nature 520:E3-E5(2015).
RN   [13]
RP   LACK OF INVOLVEMENT IN ALZHEIMER DISEASE, AND VARIANT MET-232.
RX   PubMed=25832413; DOI=10.1038/nature14040;
RA   Hooli B.V., Lill C.M., Mullin K., Qiao D., Lange C., Bertram L.,
RA   Tanzi R.E.;
RT   "PLD3 gene variants and Alzheimer's disease.";
RL   Nature 520:E7-E8(2015).
RN   [14]
RP   POSSIBLE INVOLVEMENT IN ALZHEIMER DISEASE, AND VARIANT MET-232.
RX   PubMed=25832409; DOI=10.1038/nature14041;
RA   Cruchaga C., Goate A.M.;
RT   "Cruchaga & Goate reply.";
RL   Nature 520:E10-E10(2015).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [16]
RP   INVOLVEMENT IN SCA46, VARIANT SCA46 PRO-308, AND GLYCOSYLATION.
RX   PubMed=29053796; DOI=10.1093/brain/awx251;
RA   Nibbeling E.A.R., Duarri A., Verschuuren-Bemelmans C.C., Fokkens M.R.,
RA   Karjalainen J.M., Smeets C.J.L.M., de Boer-Bergsma J.J., van der Vries G.,
RA   Dooijes D., Bampi G.B., van Diemen C., Brunt E., Ippel E., Kremer B.,
RA   Vlak M., Adir N., Wijmenga C., van de Warrenburg B.P.C., Franke L.,
RA   Sinke R.J., Verbeek D.S.;
RT   "Exome sequencing and network analysis identifies shared mechanisms
RT   underlying spinocerebellar ataxia.";
RL   Brain 140:2860-2878(2017).
RN   [17]
RP   LACK OF INVOLVEMENT IN ALZHEIMER DISEASE, TISSUE SPECIFICITY,
RP   CHARACTERIZATION OF VARIANTS MET-232, FUNCTION, AND MUTAGENESIS OF LYS-418.
RX   PubMed=28128235; DOI=10.1038/nature21030;
RA   Fazzari P., Horre K., Arranz A.M., Frigerio C.S., Saito T., Saido T.C.,
RA   De Strooper B.;
RT   "PLD3 gene and processing of APP.";
RL   Nature 541:E1-E2(2017).
RN   [18]
RP   CHARACTERIZATION OF VARIANT SCA46 PRO-308, FUNCTION, CATALYTIC ACTIVITY,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=30312375; DOI=10.1093/brain/awy258;
RA   Gonzalez A.C., Stroobants S., Reisdorf P., Gavin A.L., Nemazee D.,
RA   Schwudke D., D'Hooge R., Saftig P., Damme M.;
RT   "PLD3 and spinocerebellar ataxia.";
RL   Brain 141:E78-E78(2018).
RN   [19]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TOPOLOGY.
RX   PubMed=29368044; DOI=10.1007/s00018-018-2752-9;
RA   Mukadam A.S., Breusegem S.Y., Seaman M.N.J.;
RT   "Analysis of novel endosome-to-Golgi retrieval genes reveals a role for
RT   PLD3 in regulating endosomal protein sorting and amyloid precursor protein
RT   processing.";
RL   Cell. Mol. Life Sci. 75:2613-2625(2018).
RN   [20]
RP   SUBCELLULAR LOCATION, GLYCOSYLATION, AND MUTAGENESIS OF TYR-7.
RX   PubMed=29386126; DOI=10.1016/j.celrep.2017.12.100;
RA   Gonzalez A.C., Schweizer M., Jagdmann S., Bernreuther C., Reinheckel T.,
RA   Saftig P., Damme M.;
RT   "Unconventional Trafficking of Mammalian Phospholipase D3 to Lysosomes.";
RL   Cell Rep. 22:1040-1053(2018).
RN   [21]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=30111894; DOI=10.1038/s41590-018-0179-y;
RA   Gavin A.L., Huang D., Huber C., Maartensson A., Tardif V., Skog P.D.,
RA   Blane T.R., Thinnes T.C., Osborn K., Chong H.S., Kargaran F., Kimm P.,
RA   Zeitjian A., Sielski R.L., Briggs M., Schulz S.R., Zarpellon A.,
RA   Cravatt B., Pang E.S., Teijaro J., de la Torre J.C., O'Keeffe M.,
RA   Hochrein H., Damme M., Teyton L., Lawson B.R., Nemazee D.;
RT   "PLD3 and PLD4 are single-stranded acid exonucleases that regulate
RT   endosomal nucleic-acid sensing.";
RL   Nat. Immunol. 19:942-953(2018).
RN   [22]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=34620855; DOI=10.1038/s41467-021-26150-w;
RA   Gavin A.L., Huang D., Blane T.R., Thinnes T.C., Murakami Y., Fukui R.,
RA   Miyake K., Nemazee D.;
RT   "Cleavage of DNA and RNA by PLD3 and PLD4 limits autoinflammatory
RT   triggering by multiple sensors.";
RL   Nat. Commun. 12:5874-5874(2021).
RN   [23]
RP   FUNCTION, CATALYTIC ACTIVITY, CHARACTERIZATION OF VARIANTS MET-232; SER-284
RP   AND ALA-426, AND MUTAGENESIS OF MET-6; LYS-228 AND ASN-236.
RX   PubMed=37225734; DOI=10.1038/s41467-023-38501-w;
RA   Van Acker Z.P., Perdok A., Hellemans R., North K., Vorsters I., Cappel C.,
RA   Dehairs J., Swinnen J.V., Sannerud R., Bretou M., Damme M., Annaert W.;
RT   "Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide
RT   signaling and APP metabolism.";
RL   Nat. Commun. 14:2847-2847(2023).
RN   [24]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, MUTAGENESIS OF HIS-201;
RP   LYS-203; ASP-208; HIS-416; LYS-418 AND GLU-423, CHARACTERIZATION OF VARIANT
RP   MET-232, AND CHARACTERIZATION OF VARIANT SCA46 PRO-308.
RX   PubMed=39423811; DOI=10.1016/j.cell.2024.09.036;
RA   Singh S., Dransfeld U.E., Ambaw Y.A., Lopez-Scarim J., Farese R.V. Jr.,
RA   Walther T.C.;
RT   "PLD3 and PLD4 synthesize S,S-BMP, a key phospholipid enabling lipid
RT   degradation in lysosomes.";
RL   Cell 0:0-0(2024).
RN   [25]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, CHARACTERIZATION OF VARIANT SCA46 PRO-308, VARIANT MET-232, AND
RP   MUTAGENESIS OF ILE-163; ARG-356 AND PRO-410.
RX   PubMed=38537643; DOI=10.1016/j.str.2024.02.019;
RA   Yuan M., Peng L., Huang D., Gavin A., Luan F., Tran J., Feng Z., Zhu X.,
RA   Matteson J., Wilson I.A., Nemazee D.;
RT   "Structural and mechanistic insights into disease-associated endolysosomal
RT   exonucleases PLD3 and PLD4.";
RL   Structure 32:766-779.e7(2024).
RN   [26] {ECO:0007744|PDB:8S86}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS) OF 60-490, FUNCTION,
RP   CATALYTIC ACTIVITY, TISSUE SPECIFICITY, SUBUNIT, DOMAIN, MUTAGENESIS OF
RP   HIS-201; HIS-337; HIS-339; ARG-340; HIS-388; HIS-390; TYR-411 AND HIS-416,
RP   CHARACTERIZATION OF VARIANT SCA46 PRO-308, AND CHARACTERIZATION OF VARIANT
RP   MET-232.
RX   PubMed=38697119; DOI=10.1016/j.immuni.2024.04.010;
RA   Berouti M., Lammens K., Heiss M., Hansbauer L., Bauernfried S., Stoeckl J.,
RA   Pinci F., Piseddu I., Greulich W., Wang M., Jung C., Froehlich T.,
RA   Carell T., Hopfner K.P., Hornung V.;
RT   "Lysosomal endonuclease RNase T2 and PLD exonucleases cooperatively
RT   generate RNA ligands for TLR7 activation.";
RL   Immunity 57:1482-1496.e8(2024).
RN   [27] {ECO:0007744|PDB:8Q1K, ECO:0007744|PDB:8Q1X}
RP   X-RAY CRYSTALLOGRAPHY (1.51 ANGSTROMS) OF 72-490 IN COMPLEX WITH MG(2+),
RP   SUBUNIT, DOMAIN, GLYCOSYLATION AT ASN-97; ASN-132; ASN-236; ASN-284 AND
RP   ASN-387, PROTEOLYTIC CLEAVAGE, FUNCTION, AND MUTAGENESIS OF CYS-300;
RP   ARG-350; TYR-354; PHE-377; SER-380; LYS-418; GLU-423 AND ASN-432.
RX   PubMed=37994783; DOI=10.1093/nar/gkad1114;
RA   Roske Y., Cappel C., Cremer N., Hoffmann P., Koudelka T., Tholey A.,
RA   Heinemann U., Daumke O., Damme M.;
RT   "Structural analysis of PLD3 reveals insights into the mechanism of
RT   lysosomal 5' exonuclease-mediated nucleic acid degradation.";
RL   Nucleic Acids Res. 52:370-384(2024).
CC   -!- FUNCTION: 5'->3' exonuclease that hydrolyzes the phosphodiester bond of
CC       single-stranded DNA (ssDNA) and RNA molecules to form nucleoside 3'-
CC       monophosphates and 5'-end 5'-hydroxy deoxyribonucleotide/ribonucleotide
CC       fragments (PubMed:30111894, PubMed:30312375, PubMed:34620855,
CC       PubMed:37225734, PubMed:37994783, PubMed:38537643, PubMed:38697119).
CC       Partially redundant with PLD4, can cleave all four nucleotides
CC       displaying higher efficiency for ssDNA and RNA fragments initiated with
CC       uridine and guanosine residues and lower efficiency for cytidine-
CC       initiated substrates (PubMed:30111894, PubMed:30312375,
CC       PubMed:34620855, PubMed:37225734, PubMed:37994783, PubMed:38537643,
CC       PubMed:38697119). As a result, it does not always degrade
CC       polynucleotides to the single nucleotide level, it can stall at
CC       specific sites sparing certain fragments from exonucleolytic
CC       degradation (PubMed:30111894, PubMed:30312375, PubMed:34620855,
CC       PubMed:37225734, PubMed:37994783, PubMed:38537643, PubMed:38697119).
CC       Processes self and pathogenic ssDNA and RNA molecules that reach the
CC       endolysosomal compartment via phagocytosis or autophagy and may serve
CC       as 'danger' signals for recognition by innate immune receptors such as
CC       toll-like receptors (TLRs) (PubMed:34620855, PubMed:37225734,
CC       PubMed:38697119). Degrades mitochondrial CpG-rich ssDNA fragments to
CC       prevent TLR9 activation and autoinflammatory response, but it can
CC       cleave viral RNA to generate ligands for TLR7 activation and initiate
CC       antiviral immune responses (PubMed:34620855, PubMed:37225734,
CC       PubMed:38697119). In plasmacytoid dendritic cells, it cooperates with
CC       endonuclease RNASET2 to release 2',3'-cyclic guanosine monophosphate
CC       (2',3'-cGMP), a potent stimulatory ligand for TLR7 (PubMed:34620855,
CC       PubMed:37225734, PubMed:38697119). Produces 2',3'-cGMPs and cytidine-
CC       rich RNA fragments that occupy TLR7 ligand-binding pockets and trigger
CC       a signaling-competent state (PubMed:34620855, PubMed:37225734,
CC       PubMed:38697119). Can exert polynucleotide phosphatase activity toward
CC       5'-phosphorylated ssDNA substrates although at a slow rate
CC       (PubMed:38537643). Transphosphatidylase that catalyzes the exchange
CC       with R to S stereo-inversion of the glycerol moiety between (S,R)-
CC       lysophosphatidylglycerol (LPG) and monoacylglycerol (MAG) substrates to
CC       yield (S,S)-bis(monoacylglycero)phosphate (BMP) (PubMed:39423811). Can
CC       synthesize a variety of (S,S)-BMPs representing the main phospholipid
CC       constituent of lysosomal intralumenal vesicle (ILV) membranes that bind
CC       acid hydrolases for lipid degradation (PubMed:39423811). Regulates the
CC       homeostasis and interorganellar communication of the endolysosomal
CC       system with an overall impact on cellular removal of dysfunctional
CC       organelles via autophagy as well as proper protein and lipid turnover
CC       (PubMed:28128235, PubMed:29368044, PubMed:37225734). May play a role in
CC       myotube formation in response to ER stress (PubMed:22428023).
CC       {ECO:0000269|PubMed:22428023, ECO:0000269|PubMed:28128235,
CC       ECO:0000269|PubMed:29368044, ECO:0000269|PubMed:30111894,
CC       ECO:0000269|PubMed:30312375, ECO:0000269|PubMed:34620855,
CC       ECO:0000269|PubMed:37225734, ECO:0000269|PubMed:37994783,
CC       ECO:0000269|PubMed:38537643, ECO:0000269|PubMed:38697119,
CC       ECO:0000269|PubMed:39423811}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Exonucleolytic cleavage in the 5'- to 3'-direction to yield
CC         nucleoside 3'-phosphates.; EC=3.1.16.1;
CC         Evidence={ECO:0000269|PubMed:30111894, ECO:0000269|PubMed:30312375,
CC         ECO:0000269|PubMed:34620855, ECO:0000269|PubMed:37225734,
CC         ECO:0000269|PubMed:38537643};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 5'-end 5'-dephospho-ribonucleotidyl-ribonucleotide-RNA + H2O
CC         = a ribonucleoside 3'-phosphate + a 5'-end dephospho-ribonucleoside-
CC         RNA + H(+); Xref=Rhea:RHEA:81375, Rhea:RHEA-COMP:13936, Rhea:RHEA-
CC         COMP:19670, ChEBI:CHEBI:13197, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:138284, ChEBI:CHEBI:231871;
CC         Evidence={ECO:0000269|PubMed:34620855};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:81376;
CC         Evidence={ECO:0000305|PubMed:34620855};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a ribonucleoside 3'-phosphate-2'-3'-cyclophospho-GMP + H2O = a
CC         ribonucleoside 3'-phosphate + 2',3'-cyclophospho-GMP + H(+);
CC         Xref=Rhea:RHEA:81319, ChEBI:CHEBI:13197, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:60837, ChEBI:CHEBI:231870;
CC         Evidence={ECO:0000269|PubMed:38697119};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:81320;
CC         Evidence={ECO:0000269|PubMed:38697119};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 5'-end 5'-dephospho-2'-deoxyribonucleotidyl-2'-
CC         deoxyribonucleotide in single-stranded DNA + H2O = a 5'-end
CC         dephospho-2'-deoxyribonucleoside in single-stranded DNA + a 2'-
CC         deoxyribonucleoside 3'-phosphate + H(+); Xref=Rhea:RHEA:81379,
CC         Rhea:RHEA-COMP:19701, Rhea:RHEA-COMP:19702, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:131705, ChEBI:CHEBI:136416,
CC         ChEBI:CHEBI:231873; Evidence={ECO:0000269|PubMed:30111894,
CC         ECO:0000269|PubMed:37225734, ECO:0000269|PubMed:38537643};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:81380;
CC         Evidence={ECO:0000305|PubMed:30111894, ECO:0000305|PubMed:37225734,
CC         ECO:0000305|PubMed:38537643};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 5'-end 5'-phospho-2'-deoxyribonucleotide in single-stranded
CC         DNA + H2O = a 5'-end 5'-dephospho-2'-deoxyribonucleotide in single-
CC         stranded DNA + phosphate; Xref=Rhea:RHEA:82335, Rhea:RHEA-COMP:19868,
CC         Rhea:RHEA-COMP:19869, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:136412, ChEBI:CHEBI:136416;
CC         Evidence={ECO:0000269|PubMed:38537643};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:82336;
CC         Evidence={ECO:0000305|PubMed:38537643};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 3-lyso-sn-glycero-1-phospho-(3'-acyl-1'-sn-glycerol) + a 1-
CC         acyl-sn-glycerol = a 3-acyl-sn-glycero-1-phospho-(3'-acyl-1'-sn-
CC         glycerol) + glycerol; Xref=Rhea:RHEA:82563, ChEBI:CHEBI:17754,
CC         ChEBI:CHEBI:64683, ChEBI:CHEBI:77717, ChEBI:CHEBI:232393;
CC         Evidence={ECO:0000269|PubMed:39423811};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:82564;
CC         Evidence={ECO:0000305|PubMed:39423811};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3-lyso-sn-glycero-1-phospho-(3'-(9Z-octadecenoyl)-1'-sn-
CC         glycerol) + 1-(9Z-octadecenoyl)-sn-glycerol = 3-(9Z-octadecenoyl)-sn-
CC         glycero-1-phospho-(3'-(9Z-octadecenoyl)-1'-sn-glycerol) + glycerol;
CC         Xref=Rhea:RHEA:82567, ChEBI:CHEBI:17754, ChEBI:CHEBI:75757,
CC         ChEBI:CHEBI:139150, ChEBI:CHEBI:232394;
CC         Evidence={ECO:0000269|PubMed:39423811};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:82568;
CC         Evidence={ECO:0000305|PubMed:39423811};
CC   -!- ACTIVITY REGULATION: The exonuclease activity toward ssDNA substrate is
CC       Ca(2+) and Mg(2+)-independent, but it is inhibited by Fe(2+), Cu(2+)
CC       and to a lesser extent Zn(2+) ions. {ECO:0000269|PubMed:38537643}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=18 uM for 5'-OH ApA diribonucleotide
CC         {ECO:0000269|PubMed:34620855};
CC         KM=72 uM for 5'-OH CpA diribonucleotide
CC         {ECO:0000269|PubMed:34620855};
CC         KM=84 uM for 5'-OH UpA diribonucleotide
CC         {ECO:0000269|PubMed:34620855};
CC         KM=93 uM for 5'-OH GpA diribonucleotide
CC         {ECO:0000269|PubMed:34620855};
CC       pH dependence:
CC         Active at acidic pHs. {ECO:0000269|PubMed:30111894,
CC         ECO:0000269|PubMed:34620855, ECO:0000269|PubMed:38537643};
CC   -!- SUBUNIT: Homodimer (PubMed:37994783, PubMed:38697119). Interacts with
CC       APP. {ECO:0000269|PubMed:24336208, ECO:0000269|PubMed:37994783,
CC       ECO:0000269|PubMed:38697119}.
CC   -!- INTERACTION:
CC       Q8IV08; Q8TBE1: CNIH3; NbExp=3; IntAct=EBI-2689908, EBI-12208021;
CC       Q8IV08; P19838: NFKB1; NbExp=2; IntAct=EBI-2689908, EBI-300010;
CC       Q8IV08; P35372-10: OPRM1; NbExp=3; IntAct=EBI-2689908, EBI-12807478;
CC       Q8IV08; Q9NRQ5: SMCO4; NbExp=3; IntAct=EBI-2689908, EBI-8640191;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:15794758, ECO:0000269|PubMed:22428023}; Single-pass
CC       type II membrane protein {ECO:0000269|PubMed:15794758,
CC       ECO:0000269|PubMed:22428023}. Lysosome lumen
CC       {ECO:0000269|PubMed:29386126, ECO:0000269|PubMed:30312375,
CC       ECO:0000305|PubMed:39423811}. Early endosome membrane
CC       {ECO:0000269|PubMed:29386126}; Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:15794758, ECO:0000269|PubMed:22428023}. Late
CC       endosome membrane {ECO:0000269|PubMed:29386126}; Single-pass type II
CC       membrane protein {ECO:0000269|PubMed:15794758,
CC       ECO:0000269|PubMed:22428023}. Golgi apparatus membrane
CC       {ECO:0000269|PubMed:29368044}; Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:29368044}. Endosome membrane
CC       {ECO:0000269|PubMed:29368044}; Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:29368044}. Note=Localizes to ER-associated vesicles
CC       in differentiating myotubes (PubMed:22428023). Sorted into intralumenal
CC       vesicles (ILVs) in lysosomes. The soluble form in lysosome arises by
CC       proteolytic processing of the membrane-bound form (PubMed:29386126).
CC       Colocalizes with APP in endosomes (PubMed:29368044).
CC       {ECO:0000269|PubMed:22428023, ECO:0000269|PubMed:29368044,
CC       ECO:0000269|PubMed:29386126}.
CC   -!- TISSUE SPECIFICITY: Widely expressed. In the brain, high levels of
CC       expression are detected in the frontal, temporal and occipital cortices
CC       and hippocampus. Expressed at low level in corpus callosum. Expressed
CC       in plasmacytoid dendritic cells and monocytes (at protein level).
CC       {ECO:0000269|PubMed:15794758, ECO:0000269|PubMed:24336208,
CC       ECO:0000269|PubMed:38697119}.
CC   -!- DOMAIN: The catalytic domain contains two conserved PLD
CC       phosphodiesterase HxK(x4)D(E) motifs that accomodate the phosphate
CC       group of the nucleic acid substrates, with one nucleophile histidine
CC       residue forming a phosphohistidine intermediate and the other histidine
CC       protonating the leaving 5'-OH ssDNA/RNA fragment, resulting in the
CC       cleavage of the phosphodiester bond. The homodimer has two independent
CC       catalytic domains arranged at the dimer interface.
CC       {ECO:0000269|PubMed:37994783, ECO:0000269|PubMed:38697119}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:15794758,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:29053796,
CC       ECO:0000269|PubMed:29386126, ECO:0000269|PubMed:37994783}.
CC   -!- PTM: Proteolytically processed to a soluble active form that is stable
CC       within endosomes and lysosomes. During transport through the secretory
CC       pathway becomes proteolysed by cysteine proteases, thereby releasing a
CC       stable soluble lysosomal lumenal polypeptide, whereas the
CC       transmembrane-bound fragment is rapidly degraded. Its transport route
CC       to lysosomes involves ubiquitination and the ESCRT complex.
CC       {ECO:0000269|PubMed:29386126, ECO:0000269|PubMed:37994783}.
CC   -!- PTM: Ubiquitinated at N-terminus. Ubiquitination mediates sorting into
CC       lysosomes. {ECO:0000269|PubMed:29386126}.
CC   -!- DISEASE: Spinocerebellar ataxia 46 (SCA46) [MIM:617770]: A form of
CC       spinocerebellar ataxia, a clinically and genetically heterogeneous
CC       group of cerebellar disorders. Patients show progressive incoordination
CC       of gait and often poor coordination of hands, speech and eye movements,
CC       due to degeneration of the cerebellum with variable involvement of the
CC       brainstem and spinal cord. SCA46 is a slowly progressive, autosomal
CC       dominant form with onset in adulthood. {ECO:0000269|PubMed:29053796,
CC       ECO:0000269|PubMed:30312375, ECO:0000269|PubMed:38537643,
CC       ECO:0000269|PubMed:38697119, ECO:0000269|PubMed:39423811}. Note=The
CC       disease may be caused by variants affecting the gene represented in
CC       this entry. There is limited evidences for implication of PLD3 in
CC       SCA46. Knockout mice do not present signs of cerebellar degeneration or
CC       spinocerebellar ataxia at 9 months of age, challenging the
CC       interpretation of the suggested loss-of-function mechanism for PLD3 as
CC       the SCA46-causative gene. {ECO:0000269|PubMed:30312375}.
CC   -!- DISEASE: Note=Genetic variants in PLD3 have been suggested to be
CC       associated with an increased risk for Alzheimer disease
CC       (PubMed:24336208, PubMed:25832409). Further studies, however, did not
CC       support PLD3 involvement in this disease (PubMed:25832408,
CC       PubMed:25832410, PubMed:25832411, PubMed:25832413, PubMed:26411346).
CC       Futhermore, it is controversial whether PLD3 plays a role in amyloid
CC       precursor protein processing (APP) or not (PubMed:24336208). In a
CC       relevant Alzheimer's disease mouse model PLD3 deficiency does not
CC       affect APP metabolism or amyloid plaque burden (PubMed:28128235).
CC       However one study shown that PLD3 influences APP processing
CC       (PubMed:24336208). {ECO:0000269|PubMed:24336208,
CC       ECO:0000269|PubMed:25832408, ECO:0000269|PubMed:25832409,
CC       ECO:0000269|PubMed:25832410, ECO:0000269|PubMed:25832411,
CC       ECO:0000269|PubMed:25832413, ECO:0000269|PubMed:26411346,
CC       ECO:0000269|PubMed:28128235}.
CC   -!- SIMILARITY: Belongs to the phospholipase D family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB16799.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U60644; AAB16799.1; ALT_FRAME; mRNA.
DR   EMBL; BC000553; AAH00553.2; -; mRNA.
DR   EMBL; BC036327; AAH36327.1; -; mRNA.
DR   EMBL; BC096820; AAH96820.1; -; mRNA.
DR   CCDS; CCDS33027.1; -.
DR   RefSeq; NP_001026866.1; NM_001031696.4.
DR   RefSeq; NP_001278240.1; NM_001291311.2.
DR   RefSeq; NP_036400.2; NM_012268.4.
DR   RefSeq; XP_005258761.1; XM_005258704.1.
DR   RefSeq; XP_005258764.1; XM_005258707.4.
DR   RefSeq; XP_005258765.1; XM_005258708.3.
DR   RefSeq; XP_005258766.1; XM_005258709.4.
DR   RefSeq; XP_005258767.1; XM_005258710.4.
DR   RefSeq; XP_006723185.1; XM_006723122.1.
DR   RefSeq; XP_011524994.1; XM_011526692.1.
DR   RefSeq; XP_011524995.1; XM_011526693.1.
DR   RefSeq; XP_016882035.1; XM_017026546.1.
DR   RefSeq; XP_016882036.1; XM_017026547.1.
DR   RefSeq; XP_016882037.1; XM_017026548.1.
DR   RefSeq; XP_016882038.1; XM_017026549.1.
DR   PDB; 8Q1K; X-ray; 1.51 A; A/B=72-490.
DR   PDB; 8Q1X; X-ray; 1.85 A; A/B=61-490.
DR   PDB; 8S86; EM; 2.80 A; A/B=60-490.
DR   PDB; 8V5T; X-ray; 2.30 A; A/B=1-490.
DR   PDBsum; 8Q1K; -.
DR   PDBsum; 8Q1X; -.
DR   PDBsum; 8S86; -.
DR   PDBsum; 8V5T; -.
DR   AlphaFoldDB; Q8IV08; -.
DR   EMDB; EMD-19798; -.
DR   SMR; Q8IV08; -.
DR   BioGRID; 117173; 260.
DR   FunCoup; Q8IV08; 863.
DR   IntAct; Q8IV08; 53.
DR   MINT; Q8IV08; -.
DR   STRING; 9606.ENSP00000387050; -.
DR   BindingDB; Q8IV08; -.
DR   ChEMBL; CHEMBL2769; -.
DR   GlyConnect; 1604; 14 N-Linked glycans (3 sites).
DR   GlyCosmos; Q8IV08; 5 sites, 14 glycans.
DR   GlyGen; Q8IV08; 7 sites, 36 N-linked glycans (4 sites), 2 N-linked;o-linked glycans (1 site), 1 O-linked glycan (1 site).
DR   iPTMnet; Q8IV08; -.
DR   PhosphoSitePlus; Q8IV08; -.
DR   SwissPalm; Q8IV08; -.
DR   BioMuta; PLD3; -.
DR   DMDM; 74750647; -.
DR   jPOST; Q8IV08; -.
DR   MassIVE; Q8IV08; -.
DR   PaxDb; 9606-ENSP00000387050; -.
DR   PeptideAtlas; Q8IV08; -.
DR   ProteomicsDB; 70639; -.
DR   Pumba; Q8IV08; -.
DR   TopDownProteomics; Q8IV08; -.
DR   Antibodypedia; 2295; 133 antibodies from 24 providers.
DR   DNASU; 23646; -.
DR   Ensembl; ENST00000356508.9; ENSP00000348901.5; ENSG00000105223.21.
DR   Ensembl; ENST00000409281.5; ENSP00000387022.1; ENSG00000105223.21.
DR   Ensembl; ENST00000409419.5; ENSP00000386293.1; ENSG00000105223.21.
DR   Ensembl; ENST00000409587.5; ENSP00000387050.1; ENSG00000105223.21.
DR   Ensembl; ENST00000409735.9; ENSP00000386938.3; ENSG00000105223.21.
DR   Ensembl; ENST00000700616.1; ENSP00000515107.1; ENSG00000105223.21.
DR   Ensembl; ENST00000700619.1; ENSP00000515110.1; ENSG00000105223.21.
DR   Ensembl; ENST00000700620.1; ENSP00000515111.1; ENSG00000105223.21.
DR   Ensembl; ENST00000700621.1; ENSP00000515112.1; ENSG00000105223.21.
DR   Ensembl; ENST00000700623.1; ENSP00000515113.1; ENSG00000105223.21.
DR   Ensembl; ENST00000700625.1; ENSP00000515115.1; ENSG00000105223.21.
DR   Ensembl; ENST00000700626.1; ENSP00000515116.1; ENSG00000105223.21.
DR   Ensembl; ENST00000700628.1; ENSP00000515117.1; ENSG00000105223.21.
DR   Ensembl; ENST00000700630.1; ENSP00000515118.1; ENSG00000105223.21.
DR   Ensembl; ENST00000700631.1; ENSP00000515119.1; ENSG00000105223.21.
DR   Ensembl; ENST00000700632.1; ENSP00000515120.1; ENSG00000105223.21.
DR   Ensembl; ENST00000700633.1; ENSP00000515121.1; ENSG00000105223.21.
DR   Ensembl; ENST00000700634.1; ENSP00000515122.1; ENSG00000105223.21.
DR   Ensembl; ENST00000700637.1; ENSP00000515123.1; ENSG00000105223.21.
DR   GeneID; 23646; -.
DR   KEGG; hsa:23646; -.
DR   MANE-Select; ENST00000409735.9; ENSP00000386938.3; NM_012268.4; NP_036400.2.
DR   UCSC; uc002onj.5; human.
DR   AGR; HGNC:17158; -.
DR   CTD; 23646; -.
DR   DisGeNET; 23646; -.
DR   GeneCards; PLD3; -.
DR   HGNC; HGNC:17158; PLD3.
DR   HPA; ENSG00000105223; Tissue enhanced (pituitary).
DR   MalaCards; PLD3; -.
DR   MIM; 615698; gene.
DR   MIM; 617770; phenotype.
DR   neXtProt; NX_Q8IV08; -.
DR   OpenTargets; ENSG00000105223; -.
DR   Orphanet; 589522; Spinocerebellar ataxia type 46.
DR   PharmGKB; PA134887482; -.
DR   VEuPathDB; HostDB:ENSG00000105223; -.
DR   eggNOG; KOG3603; Eukaryota.
DR   GeneTree; ENSGT00950000183059; -.
DR   HOGENOM; CLU_027021_0_0_1; -.
DR   InParanoid; Q8IV08; -.
DR   OMA; RDNHTHF; -.
DR   OrthoDB; 1923775at2759; -.
DR   PAN-GO; Q8IV08; 0 GO annotations based on evolutionary models.
DR   PhylomeDB; Q8IV08; -.
DR   TreeFam; TF313378; -.
DR   PathwayCommons; Q8IV08; -.
DR   Reactome; R-HSA-1483148; Synthesis of PG.
DR   Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis.
DR   SignaLink; Q8IV08; -.
DR   SIGNOR; Q8IV08; -.
DR   BioGRID-ORCS; 23646; 16 hits in 1172 CRISPR screens.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   ChiTaRS; PLD3; human.
DR   GenomeRNAi; 23646; -.
DR   Pharos; Q8IV08; Tbio.
DR   PRO; PR:Q8IV08; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q8IV08; protein.
DR   Bgee; ENSG00000105223; Expressed in adenohypophysis and 197 other cell types or tissues.
DR   ExpressionAtlas; Q8IV08; baseline and differential.
DR   GO; GO:0031901; C:early endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IDA:UniProtKB.
DR   GO; GO:0031902; C:late endosome membrane; IDA:UniProtKB.
DR   GO; GO:0043202; C:lysosomal lumen; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IEA:Ensembl.
DR   GO; GO:0004630; F:phospholipase D activity; TAS:ProtInc.
DR   GO; GO:0045145; F:single-stranded DNA 5'-3' DNA exonuclease activity; IDA:UniProtKB.
DR   GO; GO:0002376; P:immune system process; IEA:UniProtKB-KW.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0006629; P:lipid metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0014902; P:myotube differentiation; IDA:UniProtKB.
DR   GO; GO:1900015; P:regulation of cytokine production involved in inflammatory response; ISS:UniProtKB.
DR   CDD; cd09144; PLDc_vPLD3_1; 1.
DR   CDD; cd09147; PLDc_vPLD3_2; 1.
DR   FunFam; 3.30.870.10:FF:000013; phospholipase D3 isoform X1; 1.
DR   FunFam; 3.30.870.10:FF:000019; phospholipase D3 isoform X1; 1.
DR   Gene3D; 3.30.870.10; Endonuclease Chain A; 2.
DR   InterPro; IPR050874; Diverse_PLD-related.
DR   InterPro; IPR032803; PLDc_3.
DR   InterPro; IPR001736; PLipase_D/transphosphatidylase.
DR   PANTHER; PTHR10185:SF16; 5'-3' EXONUCLEASE PLD3; 1.
DR   PANTHER; PTHR10185; PHOSPHOLIPASE D - RELATED; 1.
DR   Pfam; PF13918; PLDc_3; 1.
DR   SMART; SM00155; PLDc; 2.
DR   SUPFAM; SSF56024; Phospholipase D/nuclease; 2.
DR   PROSITE; PS50035; PLD; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Disease variant; Disulfide bond; Endoplasmic reticulum;
KW   Endosome; Exonuclease; Glycoprotein; Golgi apparatus; Hydrolase; Immunity;
KW   Inflammatory response; Lipid metabolism; Lysosome; Membrane;
KW   Neurodegeneration; Nuclease; Phospholipid metabolism;
KW   Proteomics identification; Reference proteome; Repeat; Signal-anchor;
KW   Spinocerebellar ataxia; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   CHAIN           1..490
FT                   /note="5'-3' exonuclease PLD3"
FT                   /id="PRO_0000280326"
FT   TOPO_DOM        1..38
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:22428023"
FT   TRANSMEM        39..59
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000269|PubMed:22428023"
FT   TOPO_DOM        60..490
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305|PubMed:22428023"
FT   DOMAIN          196..223
FT                   /note="PLD phosphodiesterase 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   DOMAIN          411..437
FT                   /note="PLD phosphodiesterase 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   ACT_SITE        201
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   ACT_SITE        201
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   ACT_SITE        203
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   ACT_SITE        208
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   ACT_SITE        416
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000250|UniProtKB:O35405"
FT   BINDING         201
FT                   /ligand="phosphate"
FT                   /ligand_id="ChEBI:CHEBI:43474"
FT                   /ligand_part="5'-phosphate 2'-deoxynucleoside residue"
FT                   /ligand_part_id="ChEBI:CHEBI:136412"
FT                   /evidence="ECO:0000250|UniProtKB:O35405"
FT   BINDING         203
FT                   /ligand="phosphate"
FT                   /ligand_id="ChEBI:CHEBI:43474"
FT                   /ligand_part="5'-phosphate 2'-deoxynucleoside residue"
FT                   /ligand_part_id="ChEBI:CHEBI:136412"
FT                   /evidence="ECO:0000250|UniProtKB:O35405"
FT   BINDING         218
FT                   /ligand="phosphate"
FT                   /ligand_id="ChEBI:CHEBI:43474"
FT                   /ligand_part="5'-phosphate 2'-deoxynucleoside residue"
FT                   /ligand_part_id="ChEBI:CHEBI:136412"
FT                   /evidence="ECO:0000250|UniProtKB:O35405"
FT   BINDING         416
FT                   /ligand="phosphate"
FT                   /ligand_id="ChEBI:CHEBI:43474"
FT                   /ligand_part="5'-phosphate 2'-deoxynucleoside residue"
FT                   /ligand_part_id="ChEBI:CHEBI:136412"
FT                   /evidence="ECO:0000250|UniProtKB:O35405"
FT   BINDING         438
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000269|PubMed:37994783,
FT                   ECO:0007744|PDB:8Q1X"
FT   SITE            71..72
FT                   /note="Cleavage; by lysosomal cysteine proteases"
FT                   /evidence="ECO:0000305|PubMed:29386126,
FT                   ECO:0000305|PubMed:37994783"
FT   CARBOHYD        97
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:37994783"
FT   CARBOHYD        132
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:37994783"
FT   CARBOHYD        236
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:37994783"
FT   CARBOHYD        284
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:37994783"
FT   CARBOHYD        387
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:37994783"
FT   DISULFID        77..239
FT                   /evidence="ECO:0000250|UniProtKB:O35405"
FT   DISULFID        81..237
FT                   /evidence="ECO:0000250|UniProtKB:O35405"
FT   DISULFID        366..487
FT                   /evidence="ECO:0000250|UniProtKB:O35405"
FT   VARIANT         63
FT                   /note="G -> S (in dbSNP:rs142070038)"
FT                   /evidence="ECO:0000269|PubMed:26411346"
FT                   /id="VAR_075905"
FT   VARIANT         76
FT                   /note="P -> A (in dbSNP:rs138674695)"
FT                   /evidence="ECO:0000269|PubMed:26411346"
FT                   /id="VAR_075906"
FT   VARIANT         159
FT                   /note="V -> M (in dbSNP:rs374184677)"
FT                   /evidence="ECO:0000269|PubMed:26411346"
FT                   /id="VAR_075907"
FT   VARIANT         162
FT                   /note="R -> C"
FT                   /evidence="ECO:0000269|PubMed:26411346"
FT                   /id="VAR_075908"
FT   VARIANT         173
FT                   /note="P -> S (in dbSNP:rs866850284)"
FT                   /evidence="ECO:0000269|PubMed:26411346"
FT                   /id="VAR_075909"
FT   VARIANT         175
FT                   /note="A -> G (in dbSNP:rs780604999)"
FT                   /evidence="ECO:0000269|PubMed:26411346"
FT                   /id="VAR_075910"
FT   VARIANT         188
FT                   /note="R -> C (in dbSNP:rs1326374111)"
FT                   /evidence="ECO:0000269|PubMed:26411346"
FT                   /id="VAR_075911"
FT   VARIANT         222
FT                   /note="R -> H (in dbSNP:rs765630414)"
FT                   /evidence="ECO:0000269|PubMed:26411346"
FT                   /id="VAR_075912"
FT   VARIANT         232
FT                   /note="V -> M (found in patients with Alzheimer disease;
FT                   uncertain significance; does not reduce either amyloid-beta
FT                   levels or APP expression; no effect on protein maturation
FT                   or trafficking to lysosomes; partial loss of dimer
FT                   formation; decreased or complete loss of exonuclease
FT                   activity toward mitochondrial CpG-rich ssDNA fragments
FT                   resulting in DNA build-up in the endolysosomal compartment,
FT                   increased TLR9 pro-inflammatory signaling and increased
FT                   mitophagy; decreased exonuclease activity toward RNA
FT                   substrate; decreased (S,S)- BMP synthase activity;
FT                   dbSNP:rs145999145)"
FT                   /evidence="ECO:0000269|PubMed:24336208,
FT                   ECO:0000269|PubMed:25832408, ECO:0000269|PubMed:25832409,
FT                   ECO:0000269|PubMed:25832410, ECO:0000269|PubMed:25832411,
FT                   ECO:0000269|PubMed:25832413, ECO:0000269|PubMed:26411346,
FT                   ECO:0000269|PubMed:28128235, ECO:0000269|PubMed:37225734,
FT                   ECO:0000269|PubMed:38537643, ECO:0000269|PubMed:38697119,
FT                   ECO:0000269|PubMed:39423811"
FT                   /id="VAR_071186"
FT   VARIANT         242
FT                   /note="R -> Q (in dbSNP:rs757965784)"
FT                   /evidence="ECO:0000269|PubMed:26411346"
FT                   /id="VAR_075913"
FT   VARIANT         249
FT                   /note="E -> G (in dbSNP:rs746715924)"
FT                   /evidence="ECO:0000269|PubMed:26411346"
FT                   /id="VAR_075914"
FT   VARIANT         272
FT                   /note="R -> C (in dbSNP:rs144312764)"
FT                   /evidence="ECO:0000269|PubMed:26411346"
FT                   /id="VAR_075915"
FT   VARIANT         284
FT                   /note="N -> S (no effect on protein maturation or
FT                   trafficking to lysosomes; displays differential exonuclease
FT                   activity depending on ssDNA sequence, showing increased
FT                   activity toward ATP6 CpG-rich ssDNA and normal activity
FT                   toward ND4LCpG-rich ssDNA; increases mitophagy rate;
FT                   dbSNP:rs200274020)"
FT                   /evidence="ECO:0000269|PubMed:26411346,
FT                   ECO:0000269|PubMed:37225734"
FT                   /id="VAR_075916"
FT   VARIANT         293
FT                   /note="A -> V (in dbSNP:rs368737000)"
FT                   /evidence="ECO:0000269|PubMed:26411346"
FT                   /id="VAR_075917"
FT   VARIANT         297
FT                   /note="P -> L"
FT                   /evidence="ECO:0000269|PubMed:26411346"
FT                   /id="VAR_075918"
FT   VARIANT         300
FT                   /note="C -> Y (in dbSNP:rs146083475)"
FT                   /evidence="ECO:0000269|PubMed:26411346"
FT                   /id="VAR_075919"
FT   VARIANT         308
FT                   /note="L -> P (in SCA46; uncertain significance; induces
FT                   retention in the ER; reduced lysosomal localization;
FT                   reduced proteolytic cleavage; loss of dimerization; loss of
FT                   exonuclease activity toward ssDNA and RNA substrates; loss
FT                   of (S,S)-BMP synthase activity; dbSNP:rs537053537)"
FT                   /evidence="ECO:0000269|PubMed:26411346,
FT                   ECO:0000269|PubMed:29053796, ECO:0000269|PubMed:30312375,
FT                   ECO:0000269|PubMed:38537643, ECO:0000269|PubMed:38697119,
FT                   ECO:0000269|PubMed:39423811"
FT                   /id="VAR_075920"
FT   VARIANT         358
FT                   /note="V -> I (in dbSNP:rs370488565)"
FT                   /evidence="ECO:0000269|PubMed:26411346"
FT                   /id="VAR_075921"
FT   VARIANT         426
FT                   /note="T -> A (no effect on protein maturation or
FT                   trafficking to lysosomes; displays differential exonuclease
FT                   activity depending on ssDNA sequence, showing increased
FT                   activity toward ATP6 CpG-rich ssDNA sequence and normal
FT                   activity toward ND4LCpG-rich ssDNA sequence; increases
FT                   mitophagy rate; dbSNP:rs745463234)"
FT                   /evidence="ECO:0000269|PubMed:26411346,
FT                   ECO:0000269|PubMed:37225734"
FT                   /id="VAR_075922"
FT   VARIANT         429
FT                   /note="G -> R (in dbSNP:rs986006936)"
FT                   /evidence="ECO:0000269|PubMed:26411346"
FT                   /id="VAR_075923"
FT   MUTAGEN         6
FT                   /note="M->R: No effect on protein maturation or trafficking
FT                   to lysosomes. Decreases exonuclease activity toward
FT                   mitochondrial CpG-rich ssDNA fragments resulting in
FT                   mitochondrial DNA build-up in the endolysosomal compartment
FT                   and increased mitophagy rate associated with accumulation
FT                   of amyloid precursor protein-derived C-terminal fragments
FT                   (APP-CTFs) in autophagosomes/autolysosomes."
FT                   /evidence="ECO:0000269|PubMed:37225734"
FT   MUTAGEN         7
FT                   /note="Y->A: Slightly increases plasma membrane
FT                   localization, does not affect delivery to lysosomes."
FT                   /evidence="ECO:0000269|PubMed:29386126"
FT   MUTAGEN         163
FT                   /note="I->M: Tends to form aggregates. Decreases
FT                   exonuclease activity toward ssDNA."
FT                   /evidence="ECO:0000269|PubMed:38537643"
FT   MUTAGEN         201
FT                   /note="H->A: Loss of (S,S)-BMP synthase activity. No effect
FT                   on protein expression or localization to lysosomes."
FT                   /evidence="ECO:0000269|PubMed:39423811"
FT   MUTAGEN         201
FT                   /note="H->N: Decreases RNA binding; when associated with
FT                   D-337 and N-416. Almost complete loss of RNA binding; when
FT                   associated with D-340 and N-416."
FT                   /evidence="ECO:0000269|PubMed:38697119"
FT   MUTAGEN         203
FT                   /note="K->A: Loss of (S,S)-BMP synthase activity. No effect
FT                   on protein expression or localization to lysosomes."
FT                   /evidence="ECO:0000269|PubMed:39423811"
FT   MUTAGEN         208
FT                   /note="D->A: Loss of (S,S)-BMP synthase activity. No effect
FT                   on protein expression or localization to lysosomes."
FT                   /evidence="ECO:0000269|PubMed:39423811"
FT   MUTAGEN         228
FT                   /note="K->R: Decreases exonuclease activity toward CpG-free
FT                   or CpG-rich ssDNA substrates. Increases mitophagy rate. No
FT                   effect on protein maturation or trafficking to lysosomes."
FT                   /evidence="ECO:0000269|PubMed:37225734"
FT   MUTAGEN         236
FT                   /note="N->S: Increases exonuclease activity toward CpG-free
FT                   ssDNA substrates. Slightly decreases exonuclease activity
FT                   toward a CpG-rich ATP6 ssDNA sequence. Loss of exonuclease
FT                   activity toward a CpG-rich ND4L ssDNA sequence. Increases
FT                   mitophagy rate. No effect on protein maturation or
FT                   trafficking to lysosomes."
FT                   /evidence="ECO:0000269|PubMed:37225734"
FT   MUTAGEN         300
FT                   /note="C->S: No effect on proteolytical processing or
FT                   localization to lysosomes."
FT                   /evidence="ECO:0000269|PubMed:37994783"
FT   MUTAGEN         337
FT                   /note="H->D: Decreases exonuclease activity toward RNA.
FT                   Decreases RNA binding; when associated with N-201 and
FT                   N-416. Results in a 10-fold reduction of exonuclease
FT                   activity toward RNA; when associated with N-339."
FT                   /evidence="ECO:0000269|PubMed:38697119"
FT   MUTAGEN         339
FT                   /note="H->D: Results in a 10-fold reduction of exonuclease
FT                   activity toward RNA; when associated with N-337."
FT                   /evidence="ECO:0000269|PubMed:38697119"
FT   MUTAGEN         340
FT                   /note="R->D: Prevents dimerization resulting in decreased
FT                   exonuclease activity toward RNA and CpG ssDNA substrates.
FT                   Almost complete loss of RNA binding; when associated with
FT                   N-201 and N-416."
FT                   /evidence="ECO:0000269|PubMed:38697119"
FT   MUTAGEN         350
FT                   /note="R->A: Retained in the endoplasmic reticulum. Loss of
FT                   exonuclease activity toward ssDNA; when associated with
FT                   A-354; A-377 and A-380."
FT                   /evidence="ECO:0000269|PubMed:37994783"
FT   MUTAGEN         354
FT                   /note="Y->A: Retained in the endoplasmic reticulum. Loss of
FT                   exonuclease activity toward ssDNA; when associated with
FT                   A-350, A-377 and A-380."
FT                   /evidence="ECO:0000269|PubMed:37994783"
FT   MUTAGEN         356
FT                   /note="R->H: No effect on exonuclease activity toward
FT                   ssDNA."
FT                   /evidence="ECO:0000269|PubMed:38537643"
FT   MUTAGEN         377
FT                   /note="F->A: Retained in the endoplasmic reticulum. Loss of
FT                   exonuclease activity toward ssDNA; when associated with
FT                   A-350; A-354 and A-380."
FT                   /evidence="ECO:0000269|PubMed:37994783"
FT   MUTAGEN         380
FT                   /note="S->A: Retained in the endoplasmic reticulum. Loss of
FT                   exonuclease activity toward ssDNA; when associated with
FT                   A-350; A-354 and A-377."
FT                   /evidence="ECO:0000269|PubMed:37994783"
FT   MUTAGEN         388
FT                   /note="H->D: No effect on exonuclease activity toward RNA
FT                   and CpG ssDNA."
FT                   /evidence="ECO:0000269|PubMed:38697119"
FT   MUTAGEN         390
FT                   /note="H->D: No effect on exonuclease activity toward RNA
FT                   and CpG ssDNA."
FT                   /evidence="ECO:0000269|PubMed:38697119"
FT   MUTAGEN         410
FT                   /note="P->S: No effect on exonuclease activity toward
FT                   ssDNA."
FT                   /evidence="ECO:0000269|PubMed:38537643"
FT   MUTAGEN         411
FT                   /note="Y->A: Decreases exonuclease activity toward RNA and
FT                   ssDNA."
FT                   /evidence="ECO:0000269|PubMed:38697119"
FT   MUTAGEN         416
FT                   /note="H->A: Loss of (S,S)-BMP synthase activity. No effect
FT                   on protein expression or localization to lysosomes."
FT                   /evidence="ECO:0000269|PubMed:39423811"
FT   MUTAGEN         416
FT                   /note="H->N: Decreases RNA binding; when associated with
FT                   N-201 and D-337. Almost complete loss of RNA binding; when
FT                   associated with N-201 and D-340."
FT                   /evidence="ECO:0000269|PubMed:38697119"
FT   MUTAGEN         418
FT                   /note="K->A: Loss of (S,S)-BMP synthase activity. Loss of
FT                   exonuclease activity toward ssDNA. No effect on protein
FT                   expression or localization to lysosomes."
FT                   /evidence="ECO:0000269|PubMed:39423811"
FT   MUTAGEN         418
FT                   /note="K->R: Impairs myotube formation. Loss of exonuclease
FT                   activity toward ssDNA. No effect on localization to
FT                   lysosomes."
FT                   /evidence="ECO:0000269|PubMed:22428023,
FT                   ECO:0000269|PubMed:28128235, ECO:0000269|PubMed:37994783"
FT   MUTAGEN         423
FT                   /note="E->A: Loss of (S,S)-BMP synthase activity. No effect
FT                   on protein expression or localization to lysosomes. Loss of
FT                   exonuclease activity toward ssDNA."
FT                   /evidence="ECO:0000269|PubMed:37994783,
FT                   ECO:0000269|PubMed:39423811"
FT   MUTAGEN         423
FT                   /note="E->D: No effect on (S,S)-BMP synthase activity,
FT                   protein expression or localization to lysosomes."
FT                   /evidence="ECO:0000269|PubMed:39423811"
FT   MUTAGEN         432
FT                   /note="N->A: Loss of exonuclease activity toward ssDNA. No
FT                   effect on protein localization to lysosomes."
FT                   /evidence="ECO:0000269|PubMed:37994783"
FT   CONFLICT        473
FT                   /note="S -> I (in Ref. 1; AAB16799)"
FT                   /evidence="ECO:0000305"
FT   STRAND          79..88
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   HELIX           105..115
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          117..125
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   HELIX           131..134
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   HELIX           139..141
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   HELIX           142..151
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   TURN            152..154
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   HELIX           155..157
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          160..166
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   HELIX           175..183
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          186..190
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   HELIX           192..196
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          204..207
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   TURN            208..210
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          211..216
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   HELIX           222..225
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          227..236
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   HELIX           238..254
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   HELIX           267..269
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          274..277
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          279..283
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          286..295
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   HELIX           297..299
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   HELIX           307..317
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          319..327
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          331..333
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   HELIX           344..356
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          359..365
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   HELIX           374..382
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   TURN            387..390
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          391..398
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   HELIX           404..407
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          413..415
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          418..424
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          426..431
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   HELIX           436..439
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          441..449
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          451..455
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   HELIX           456..469
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          473..475
FT                   /evidence="ECO:0007829|PDB:8S86"
FT   HELIX           480..482
FT                   /evidence="ECO:0007829|PDB:8Q1K"
FT   STRAND          483..485
FT                   /evidence="ECO:0007829|PDB:8Q1K"
SQ   SEQUENCE   490 AA;  54705 MW;  444EC4D02F5610F1 CRC64;
     MKPKLMYQEL KVPAEEPANE LPMNEIEAWK AAEKKARWVL LVLILAVVGF GALMTQLFLW
     EYGDLHLFGP NQRPAPCYDP CEAVLVESIP EGLDFPNAST GNPSTSQAWL GLLAGAHSSL
     DIASFYWTLT NNDTHTQEPS AQQGEEVLRQ LQTLAPKGVN VRIAVSKPSG PQPQADLQAL
     LQSGAQVRMV DMQKLTHGVL HTKFWVVDQT HFYLGSANMD WRSLTQVKEL GVVMYNCSCL
     ARDLTKIFEA YWFLGQAGSS IPSTWPRFYD TRYNQETPME ICLNGTPALA YLASAPPPLC
     PSGRTPDLKA LLNVVDNARS FIYVAVMNYL PTLEFSHPHR FWPAIDDGLR RATYERGVKV
     RLLISCWGHS EPSMRAFLLS LAALRDNHTH SDIQVKLFVV PADEAQARIP YARVNHNKYM
     VTERATYIGT SNWSGNYFTE TAGTSLLVTQ NGRGGLRSQL EAIFLRDWDS PYSHDLDTSA
     DSVGNACRLL
//
